查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1947958

银屑病IL-17抑制剂市场：按产品、适应症、分销管道、最终用户、治疗方法、给药频率和患者类型分類的全球预测（2026-2032年）

IL-17 Inhibitors for Psoriasis Market by Product, Indication, Distribution Channel, End User, Therapeutic Regimen, Dosing Frequency, Patient Type - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 189 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，用于治疗干癣的 IL-17 抑制剂市场价值将达到 23.3 亿美元，到 2026 年将成长至 24.6 亿美元，复合年增长率为 5.86%，到 ​​2032 年将达到 34.8 亿美元。

关键市场统计数据
基准年 2025 23.3亿美元
预计年份：2026年 24.6亿美元
预测年份 2032 34.8亿美元
复合年增长率 (%) 5.86%

为IL-17抑制剂在皮肤病学和风湿病学治疗路径中的应用，以及在各种医疗保健机构中的应用，提供临床、商业性和营运方面的背景资讯。

IL-17抑制剂类药物重新定义了免疫介导性皮肤病的治疗方法，为中重度斑块型干癣及伴随干癣性关节炎患者提供了强效的标靶标靶治疗选择。本文回顾了目前治疗策略的机制原理、临床定位和商业性趋势。透过聚焦于直接调节IL-17通路的药物，临床医生现在拥有了一种新的选择，该选择能够快速改善皮肤症状，提供持久的疗效，并可实现差异化的给药方案，从而提高患者的依从性并促进其与医疗保健系统的整合。

关键的临床、监管和商业性转折点将重塑IL-17疗法在现代医疗保健环境中的应用及其在竞争格局中的定位。

IL-17抑制剂领域正经历变革性的转变，这主要得益于临床的成熟、监管的演变以及商业性创新。在临床方面，越来越多的证据表明其具有长期疗效、安全性和真实世界有效性，从而优化了患者选择和治疗顺序。这促成了更精细的治疗路径，优先考虑针对重症患者或需要快速控制病情患者的速效药物，以及兼顾给药便利性和安全性的维持治疗策略。

预计美国在2025年将进行的关税调整将对IL-17疗法的生物製药供应链、定价动态和市场进入策略造成动态。

美国计划于2025年调整关税，将为生物製药供应链带来新的复杂性，影响原材料、原料药药物成分的采购以及跨境生产的经济效益。依赖进口国际原料和成品的製造商将面临到岸成本的重新调整，这可能导致与供应商和物流合作伙伴重新谈判合约。为此，供应链领导者正在重新评估供应商多元化、近岸外包能力和库存策略，以降低进口关税上涨的风险。

基于深度细分的智慧分析揭示了驱动市场动态的产品、适应症、通路、最终用户、治疗方法、剂量和患者群体动态。

细分市场分析揭示了不同产品、适应症、管道、终端用户、治疗方法、给药频率和患者群体之间存在的显着商业性和临床动态差异，这些差异影响着治疗定位和营运重点。在比较Brodalumab、ixekizumab 和 sectinimab 等药物时，其作用机制、起效时间和适应症范围的细微差别会影响处方医生的偏好和生命週期策略。适应症的具体考虑导致斑块型干癣和干癣性关节炎的用药存在差异，而关节受累则需要与风湿病学诊疗路径合作以及多学科诊疗协调。

全面的区域观点，重点在于美洲、欧洲、中东和非洲以及亚太地区的准入、监管和供应的重要性。

区域趋势将对IL-17抑制剂的临床实践、监管方法和商业策略产生深远影响。在美洲，完善的支付方体系、成熟的专科药房生态系统以及临床医生对药物的积极采纳，共同营造了一种环境，既能促进新型疗法的快速应用，又能确保支付方进行严格的审核，并协商确定准入途径。市场参与企业致力于证明药物价值、产生疗效数据，并建构支持长期用药依从性的整合式医疗模式。

为了保持 IL-17 抑制剂业务的强大基础，製造商们正在采取策略性的企业方法，强调临床差异化、生命週期延长和生态系统合作。

IL-17抑制剂领域的主要企业正在临床开发、生命週期管理和商业营运等各个环节实施差异化策略。拥有成熟产品的製造商正致力于透过长期疗效研究、安全性监测计画以及头对头或真实世界对比分析来提升产品的临床价值。这些努力有助于处方集继续纳入药品目录，并与支付方进行谈判，同时也有助于产品被纳入指南和获得专业学会的推荐。

製造商和相关人员在确保获得IL-17疗法、增强供应韧性和促进持续应用方面面临的实际策略挑战

在不断变化的市场动态中，产业领导者应采取一系列综合措施，以保障患者用药、优化商业性绩效并强化供应链。首先，应投资于强有力的真实世界证据项目，量化皮肤科和风湿病科的治疗效果、安全性和依从性，从而支持与支付方和医疗系统开展基于价值的对话。结合药物经济模型和病患报告结局，这将有助于提升药物在药品目录上的排名，并增强医保报销谈判的筹码。

一项透明的混合方法研究框架，结合系统性回顾、专家访谈和资料检验，旨在产生可操作的IL-17抑制剂见解。

本研究采用混合方法，结合系统性文献回顾、有针对性的初步研究以及专家访谈三角验证，以确保分析的严谨性。证据基础包括同行评审的临床试验、监管申报文件、指南声明以及真实世界观察性研究，旨在捕捉不同治疗环境下的疗效、安全性和使用模式。初步研究包括对皮肤科和风湿科的关键管理人员、供应链管理人员、专科药房营运人员以及支付方代表进行结构化访谈，以将临床发现与实际营运情况联繫起来。

这份简明扼要、综合全面的分析报告重点阐述了临床差异化、供应韧性和适应性商业模式三者之间的交集，这些因素将决定IL-17疗法的长期成功。

总之，IL-17抑制剂是治疗层级在斑块型干癣和干癣性关节炎治疗中日益成熟的重要治疗药物，在提供显着临床效益的同时，也面临着运作和商业上的复杂性。适应症、患者群体和给药方案的不断演变，要求我们采取积极主动的生命週期管理、重点开展循证研究以及製定以治疗连续性为优先的适应性分销策略。

目录

第一章：序言

第二章调查方法

  • 研究设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查前提
  • 调查限制

第三章执行摘要

  • 首席体验长观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会地图
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 干癣IL-17抑制剂市场（依产品分类）

  • Brodalumab
  • 伊克珠单抗
  • 塞克替尼单抗

9. IL-17抑制剂在干癣治疗的市场（依适应症划分）

  • 斑块型干癣
  • 干癣性关节炎

10. 银屑病IL-17抑制剂市场（依分销管道划分）

  • 医院药房
  • 网路药房
  • 零售药房
    • 链
    • 独立的

11. 银屑病IL-17抑制剂市场（依最终用户划分）

  • 居家医疗环境
  • 医院
  • 专科诊所

12. IL-17抑制剂在干癣治疗中的市场（依治疗方法）

  • 联合治疗
    • Cyclosporine
    • 胺基甲基叶酸
  • 单药治疗

13. 依给药频率分類的用于治疗干癣的IL-17抑制剂市场

  • 每隔一周
  • 每月一次

14. 干癣IL-17抑制剂市场（依患者类型划分）

  • 成人
  • 小儿科
    • 青春期
    • 儿童

15. 各地区干癣IL-17抑制剂市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

16. 银屑病IL-17抑制剂市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

17. 各国银屑病IL-17抑制剂市场

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

18. 美国用于治疗干癣的IL-17抑制剂市场

19. 中国：用于治疗干癣的IL-17抑制剂市场

第20章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • AbbVie Inc.
  • Almirall, SA
  • Amgen Inc.
  • AstraZeneca PLC
  • Boehringer Ingelheim International GmbH
  • Bristol Myers Squibb Company
  • Celgene Corporation
  • Eli Lilly and Company
  • Galderma SA
  • Johnson & Johnson
  • LEO Pharma A/S
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis AG
  • Pfizer Inc.
  • Sanofi SA
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • UCB SA
  • Valeant Pharmaceuticals International, Inc.
Product Code: MRR-4F7A6D4FB6A8

The IL-17 Inhibitors for Psoriasis Market was valued at USD 2.33 billion in 2025 and is projected to grow to USD 2.46 billion in 2026, with a CAGR of 5.86%, reaching USD 3.48 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 2.33 billion
Estimated Year [2026] USD 2.46 billion
Forecast Year [2032] USD 3.48 billion
CAGR (%) 5.86%

Framing the clinical, commercial, and operational context for IL-17 inhibitors in dermatology and rheumatology treatment pathways across care settings

The IL-17 inhibitor class has redefined therapeutic approaches for immune-mediated skin disease, delivering potent pathway-targeted options for patients with moderate to severe plaque psoriasis and for those with concomitant psoriatic arthritis. This introduction summarizes the mechanistic rationale, clinical positioning, and commercial dynamics that underpin current treatment strategies. By focusing on agents that directly modulate the IL-17 axis, clinicians have gained alternatives that offer rapid skin clearance, durable responses, and differentiated dosing regimens that influence adherence and health system integration.

Across treatment settings, payers and providers are balancing clinical benefits against safety profiles, long-term data, and total cost of care. The interplay between monotherapy and combination regimens, the expansion of dosing frequency options, and the growing consideration of pediatric populations are reshaping prescribing algorithms. Simultaneously, distribution and access pathways-from hospital formularies to online specialty pharmacies and community retail networks-are evolving to support diverse end users, including home care and specialty clinic models.

This introduction sets the stage for a deeper analysis by highlighting the class's therapeutic strengths, the operational levers that affect uptake, and the strategic inflection points that stakeholders should monitor. Subsequent sections examine structural market shifts, tariff and supply chain influences, segmentation-driven insights, and practical actions leaders can take to optimize patient outcomes and commercial performance.

Critical clinical, regulatory, and commercial inflection points reshaping adoption and competitive positioning of IL-17 therapies in contemporary care environments

The IL-17 inhibitor landscape is undergoing transformative shifts driven by clinical maturation, regulatory evolution, and commercial innovation. On the clinical front, expanding evidence on long-term efficacy, safety, and real-world effectiveness is refining patient selection and sequencing decisions. This has led to more nuanced treatment pathways where rapid onset agents are prioritized for severe cases or those requiring swift disease control, while dosing convenience and safety profiles inform maintenance strategies.

Regulatory and label developments have broadened the addressable patient population, prompting manufacturers to reassess orphan and pediatric strategies as appropriate. Commercially, the introduction of flexible distribution models-including enhanced specialty pharmacy programs and direct-to-patient support-has altered how therapies are delivered and supported. These changes are reinforced by payer policies that increasingly emphasize outcomes, step therapy exceptions for high clinical need, and value-based contracting pilots that tie reimbursement to real-world results.

Product lifecycle management is another major vector of change. Biologics manufacturers are optimizing dosing regimens, exploring combination approaches with conventional systemic agents, and investing in patient support infrastructure to sustain adherence. In parallel, competitors are differentiating through device innovation, user experience, and digital therapeutics that complement biologic treatment. Taken together, these shifts create a dynamic environment in which clinical differentiation, supply reliability, and adaptive commercial models determine competitive success.

How anticipated 2025 tariff shifts in the United States will pressure biologics supply chains, pricing dynamics, and market access strategies for IL-17 therapies

Projected tariff adjustments in the United States for 2025 introduce a new layer of complexity for biologics supply chains, affecting raw materials, active pharmaceutical ingredient sourcing, and cross-border manufacturing economics. Manufacturers that rely on internationally sourced inputs or finished product importation will face recalibrated landed costs, which could prompt contract renegotiations with suppliers and logistics partners. In anticipation, supply chain leaders are reassessing supplier diversification, nearshoring capacities, and inventory strategies to mitigate exposure to elevated import duties.

Healthcare systems and payers may respond by intensifying cost-containment measures, scrutinizing reimbursement pathways, and accelerating formulary reviews that emphasize total cost of care rather than list price alone. At the same time, manufacturers can pursue alternative mitigations such as localized fill-and-finish facilities, strategic partnerships with domestic contract manufacturing organizations, or bilateral supplier agreements that lock in favorable terms. These operational changes have implications for launch sequencing, pricing strategies, and market access timelines.

Patient access programs and distribution agreements are also likely to be revisited. Specialty pharmacies, hospital procurement teams, and retail networks must adapt to potential shifts in pricing and availability, while clinicians will need clear guidance on therapeutic equivalents and interchangeability where alternative sourcing becomes necessary. Regulators and industry groups will play a role in smoothing transition pathways, emphasizing continuity of care and supply while stakeholders enact commercially viable responses to tariff-driven cost pressures.

Detailed segmentation-driven intelligence uncovering product, indication, channel, end user, regimen, dosing, and patient cohort dynamics that determine market behavior

Segmentation analysis reveals distinct commercial and clinical dynamics across products, indications, channels, end users, regimens, dosing frequencies, and patient cohorts that shape therapeutic positioning and operational priorities. When comparing agents such as brodalumab, ixekizumab, and secukinumab, differences in mechanism nuance, onset of action, and label breadth inform prescriber preference and lifecycle tactics. Indication-specific considerations differentiate use in plaque psoriasis versus psoriatic arthritis, with joint involvement prompting integration with rheumatology pathways and multidisciplinary care coordination.

Distribution strategies vary with channel characteristics: hospital pharmacies focus on formulary negotiation and inpatient continuity; online pharmacies emphasize convenience, adherence support, and specialty fulfillment capabilities; retail pharmacy networks-including chain and independent outlets-drive community-level access and patient counseling. End users show divergent needs: home care settings prioritize simplified administration and remote monitoring, hospitals require reliable inpatient supply and infusion logistics, and specialty clinics depend on integrated nurse-led training and follow-up programs.

Therapeutic regimens also influence adoption patterns. Monotherapy remains central for many patients, while combination approaches incorporating cyclosporine or methotrexate are considered for rapid control or to manage partial responders. Dosing frequency-biweekly versus monthly-affects adherence, clinic throughput, and patient preference, with more frequent dosing sometimes translating to faster clinical response but higher administration touchpoints. Finally, patient-type segmentation between adult and pediatric populations, including adolescent and child subgroups, necessitates tailored safety monitoring, formulation considerations, and support programs to address distinct adherence and caregiver needs.

Comprehensive regional perspectives highlighting access, regulatory, and supply imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific territories

Regional dynamics exert a powerful influence on clinical practice, regulatory approaches, and commercial strategies for IL-17 inhibitors. In the Americas, established payer frameworks, advanced specialty pharmacy ecosystems, and strong clinician adoption patterns create an environment where rapid uptake of novel therapeutics is balanced by intensive payer scrutiny and negotiated access pathways. Market participants focus on value demonstration, outcomes data generation, and integrated care models that support long-term adherence.

Within Europe, the Middle East, and Africa, heterogeneity in regulatory timelines, reimbursement regimes, and healthcare infrastructure requires differentiated entry strategies. Some jurisdictions favor centralized evaluations and health-technology assessments that emphasize comparative effectiveness, while others prioritize cost-containment and tiered access. Manufacturers often deploy region-specific evidence packages, local medical affairs engagement, and targeted pricing approaches to navigate this mosaic.

Asia-Pacific presents a mix of mature and emerging markets with growing demand for advanced biologics, expanding specialty distribution networks, and increasing investment in domestic manufacturing capabilities. Stakeholders in this region concentrate on regulatory harmonization efforts, pathway simplification for biosimilar competition, and public-private partnerships to broaden access. Across all regions, cross-border supply chain resilience, reimbursement alignment, and culturally informed patient support programs remain critical to sustainable adoption and equitable access.

Strategic corporate approaches among manufacturers emphasizing clinical differentiation, lifecycle expansion, and ecosystem partnerships to sustain IL-17 franchise strength

Leading companies in the IL-17 inhibitor space are executing differentiated strategies across clinical development, lifecycle management, and commercial operations. Manufacturers with established products focus on reinforcing clinical value through long-term outcome studies, safety surveillance programs, and head-to-head or real-world comparative analyses. These initiatives support formulary retention and payer negotiations while informing guideline inclusion and specialty society endorsements.

Competitive response strategies include investment in patient support services, digital adherence tools, and nurse-led education to reduce friction at initiation and during maintenance therapy. Business development activity-ranging from licensing deals to localized manufacturing partnerships-enables companies to expand geographic reach and optimize supply chain resiliency. At the same time, firms are exploring label expansions into younger populations and additional immune-mediated indications, subject to robust pediatric and safety data.

Smaller entrants and specialty biotechs concentrate on niche differentiation, focusing on device innovation, novel dosing paradigms, or combination approaches to complement established therapies. Across the board, successful companies balance scientific leadership with pragmatic commercial execution, ensuring that regulatory approvals are matched by reimbursement strategies, distribution partnerships, and provider engagement plans that drive real-world uptake.

Actionable strategic imperatives for manufacturers and stakeholders to secure access, strengthen supply resilience, and drive sustained adoption of IL-17 therapies

Industry leaders should pursue an integrated set of actions to protect patient access, optimize commercial performance, and fortify supply chains amid evolving market dynamics. First, invest in robust real-world evidence programs that quantify outcomes, safety, and adherence across both dermatology and rheumatology practices to support value-based conversations with payers and health systems. Complementary pharmacoeconomic modeling and patient-reported outcomes will strengthen formulary positioning and reimbursement negotiations.

Second, diversify sourcing and manufacturing footprints to reduce exposure to tariff-related disruptions and international supply volatility. Nearshoring fill-and-finish operations, establishing redundant API suppliers, and creating flexible inventory strategies will preserve continuity of care and limit margin pressure. Third, enhance patient support offerings by aligning dosing convenience with digital adherence tools, nurse education, and streamlined home administration programs to improve persistence and satisfaction.

Fourth, tailor regional market entry plans that account for heterogeneous regulatory and reimbursement environments, deploying localized evidence and pricing strategies. Finally, build strategic alliances across stakeholders-payers, providers, specialty pharmacies, and patient advocacy groups-to co-design access solutions and outcomes-based agreements that balance clinical need with economic sustainability. These actions collectively position organizations to respond nimbly to clinical, commercial, and policy shifts.

Transparent mixed-methods research framework combining systematic review, expert primary interviews, and data triangulation to generate actionable IL-17 inhibitor insights

This research synthesis integrates a mixed-methods approach combining systematic literature review, targeted primary research, and triangulation with expert interviews to ensure analytical rigor. The evidence base includes peer-reviewed clinical trials, regulatory filings, guideline statements, and real-world observational studies to capture efficacy, safety, and utilization patterns across therapeutic contexts. Primary research comprised structured interviews with key opinion leaders in dermatology and rheumatology, supply chain executives, specialty pharmacy operators, and payer representatives to contextualize clinical findings within operational realities.

Data triangulation was performed by cross-referencing public regulatory documents with proprietary interview insights and distribution channel intelligence. Segmentation analyses leveraged product characteristics, indication-specific considerations, channel modalities, end user needs, therapeutic regimens, dosing schedules, and patient demographics to construct actionable profiles for stakeholders. Scenario analysis explored tariff-induced supply disruptions, pricing responses, and mitigation strategies without relying on single-source assumptions.

Limitations include the evolving nature of regulatory labels and ongoing post-marketing surveillance, which can affect long-term safety and pediatric use considerations. To mitigate this, the methodology emphasizes transparency in data sources, clear attribution of expert opinion, and a modular framework that permits timely updates as new clinical or policy information becomes available.

Concise synthesis highlighting the intersection of clinical differentiation, supply resilience, and adaptive commercial models that will determine long-term success for IL-17 therapies

In summary, IL-17 inhibitors represent a mature and strategically important therapeutic class for the treatment of plaque psoriasis and psoriatic arthritis, offering compelling clinical benefits alongside operational and commercial complexity. The ongoing evolution of labels, patient cohorts, and dosing paradigms necessitates proactive lifecycle management, focused evidence generation, and adaptable distribution strategies that prioritize continuity of care.

Tariff and supply chain pressures expected to materialize in the near term underscore the need for strategic sourcing and regional manufacturing considerations. At the same time, payer emphasis on outcomes and value creates opportunities for manufacturers that can demonstrate durable clinical benefit and deliver robust patient support. Regional nuances require tailored market access approaches, while segmentation-driven tactics ensure that product, channel, and patient-type strategies are aligned with clinical realities and commercial objectives.

Leaders who integrate clinical evidence, supply resilience, and pragmatic commercialization will be best positioned to maintain and grow access for patients. Continued investment in real-world data, stakeholder engagement, and flexible operational models will determine who captures long-term value in this competitive therapeutic arena.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. IL-17 Inhibitors for Psoriasis Market, by Product

  • 8.1. Brodalumab
  • 8.2. Ixekizumab
  • 8.3. Secukinumab

9. IL-17 Inhibitors for Psoriasis Market, by Indication

  • 9.1. Plaque Psoriasis
  • 9.2. Psoriatic Arthritis

10. IL-17 Inhibitors for Psoriasis Market, by Distribution Channel

  • 10.1. Hospital Pharmacies
  • 10.2. Online Pharmacies
  • 10.3. Retail Pharmacies
    • 10.3.1. Chain
    • 10.3.2. Independent

11. IL-17 Inhibitors for Psoriasis Market, by End User

  • 11.1. Home Care Settings
  • 11.2. Hospitals
  • 11.3. Specialty Clinics

12. IL-17 Inhibitors for Psoriasis Market, by Therapeutic Regimen

  • 12.1. Combination Therapy
    • 12.1.1. Cyclosporine
    • 12.1.2. Methotrexate
  • 12.2. Monotherapy

13. IL-17 Inhibitors for Psoriasis Market, by Dosing Frequency

  • 13.1. Biweekly
  • 13.2. Monthly

14. IL-17 Inhibitors for Psoriasis Market, by Patient Type

  • 14.1. Adult
  • 14.2. Pediatric
    • 14.2.1. Adolescent
    • 14.2.2. Child

15. IL-17 Inhibitors for Psoriasis Market, by Region

  • 15.1. Americas
    • 15.1.1. North America
    • 15.1.2. Latin America
  • 15.2. Europe, Middle East & Africa
    • 15.2.1. Europe
    • 15.2.2. Middle East
    • 15.2.3. Africa
  • 15.3. Asia-Pacific

16. IL-17 Inhibitors for Psoriasis Market, by Group

  • 16.1. ASEAN
  • 16.2. GCC
  • 16.3. European Union
  • 16.4. BRICS
  • 16.5. G7
  • 16.6. NATO

17. IL-17 Inhibitors for Psoriasis Market, by Country

  • 17.1. United States
  • 17.2. Canada
  • 17.3. Mexico
  • 17.4. Brazil
  • 17.5. United Kingdom
  • 17.6. Germany
  • 17.7. France
  • 17.8. Russia
  • 17.9. Italy
  • 17.10. Spain
  • 17.11. China
  • 17.12. India
  • 17.13. Japan
  • 17.14. Australia
  • 17.15. South Korea

18. United States IL-17 Inhibitors for Psoriasis Market

19. China IL-17 Inhibitors for Psoriasis Market

20. Competitive Landscape

  • 20.1. Market Concentration Analysis, 2025
    • 20.1.1. Concentration Ratio (CR)
    • 20.1.2. Herfindahl Hirschman Index (HHI)
  • 20.2. Recent Developments & Impact Analysis, 2025
  • 20.3. Product Portfolio Analysis, 2025
  • 20.4. Benchmarking Analysis, 2025
  • 20.5. AbbVie Inc.
  • 20.6. Almirall, S.A.
  • 20.7. Amgen Inc.
  • 20.8. AstraZeneca PLC
  • 20.9. Boehringer Ingelheim International GmbH
  • 20.10. Bristol Myers Squibb Company
  • 20.11. Celgene Corporation
  • 20.12. Eli Lilly and Company
  • 20.13. Galderma S.A.
  • 20.14. Johnson & Johnson
  • 20.15. LEO Pharma A/S
  • 20.16. Merck & Co., Inc.
  • 20.17. Mylan N.V.
  • 20.18. Novartis AG
  • 20.19. Pfizer Inc.
  • 20.20. Sanofi SA
  • 20.21. Sun Pharmaceutical Industries Ltd.
  • 20.22. Teva Pharmaceutical Industries Ltd.
  • 20.23. UCB S.A.
  • 20.24. Valeant Pharmaceuticals International, Inc.

LIST OF FIGURES

  • FIGURE 1. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 15. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY BRODALUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY BRODALUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY BRODALUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY IXEKIZUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY IXEKIZUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY IXEKIZUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SECUKINUMAB, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SECUKINUMAB, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SECUKINUMAB, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PLAQUE PSORIASIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PLAQUE PSORIASIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PLAQUE PSORIASIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PSORIATIC ARTHRITIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITAL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ONLINE PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ONLINE PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CHAIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CHAIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CHAIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDEPENDENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDEPENDENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDEPENDENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOME CARE SETTINGS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOME CARE SETTINGS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOME CARE SETTINGS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SPECIALTY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SPECIALTY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CYCLOSPORINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CYCLOSPORINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CYCLOSPORINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY METHOTREXATE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY METHOTREXATE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY METHOTREXATE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY BIWEEKLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY BIWEEKLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY BIWEEKLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY MONTHLY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY MONTHLY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY MONTHLY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ADULT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ADULT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ADULT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ADOLESCENT, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ADOLESCENT, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY ADOLESCENT, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CHILD, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CHILD, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY CHILD, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 83. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 84. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 85. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 86. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 93. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 95. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 96. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 104. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 106. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 115. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 116. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. MIDDLE EAST IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 157. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. AFRICA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 167. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 168. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 169. ASIA-PACIFIC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 170. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 178. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 179. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 180. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 181. ASEAN IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 182. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 183. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 184. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 185. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 186. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 187. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 189. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 190. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 191. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 192. GCC IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPEAN UNION IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 208. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 209. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 211. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 212. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 213. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. BRICS IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 215. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 216. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 217. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 218. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 219. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 220. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 221. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 222. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 223. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 224. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 225. G7 IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 226. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 227. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 228. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 229. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 230. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 231. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 232. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 233. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 234. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 235. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 236. NATO IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 237. GLOBAL IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 239. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 240. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 241. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 242. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 243. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 244. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 245. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED STATES IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)
  • TABLE 249. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 250. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PRODUCT, 2018-2032 (USD MILLION)
  • TABLE 251. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 252. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 253. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY RETAIL PHARMACIES, 2018-2032 (USD MILLION)
  • TABLE 254. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY THERAPEUTIC REGIMEN, 2018-2032 (USD MILLION)
  • TABLE 256. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY COMBINATION THERAPY, 2018-2032 (USD MILLION)
  • TABLE 257. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY DOSING FREQUENCY, 2018-2032 (USD MILLION)
  • TABLE 258. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 259. CHINA IL-17 INHIBITORS FOR PSORIASIS MARKET SIZE, BY PEDIATRIC, 2018-2032 (USD MILLION)